Post-Traumatic Stress Disorder
Conditions
Keywords
Post-Traumatic Stress Disorder, PTSD, dTMS
Brief summary
The purpose of the present study is to evaluate the safety and efficacy of Brainsway Deep TMS (DTMS) for the treatment of PTSD.
Detailed description
Deep TMS in conjunction with brief trauma exposure will be compared to sham treatment in conjunction with brief trauma exposure, in a multicenter, randomized, controlled study for the treatment of PTSD. Study duration is 9 weeks, consisting of 4 weeks of treatment and a 5 week and 9 week follow-up visit. Subjects will be randomized to real or sham treatment stratified by site. The design is meant to demonstrate that the device shows superiority compared to sham treatment at the 5 week follow-up visit and at the 9 week follow-up visit, 1 month post-treatment.
Interventions
DEVICEDeep TMS System
Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
DEVICESham Treatment
Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
Sponsors
Brainsway
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
22 Years to 68 Years
Healthy volunteers
No
Inclusion criteria
* Outpatients * Men and women 22-68 years of age * Subjects currently diagnosed with PTSD according to the DSM-5, using the CAPS-5 (past-month version), with the following criteria met: * Criterion B: at least 1/5 intrusion symptoms; and * Criteria C: at least 1/2 avoidance symptoms; and * Criteria D: at least 2/7 cognition & mood symptoms; and * Criteria E: at least 2/6 arousal & reactivity symptoms; and * Criterion F: duration is met; and * Criteria G: distress is met. * Subjects with at least moderate PTSD with a CAPS-5 score ≥ 25 at both Screening and Baseline visits. * Subjects with an HDRS-21 score ≤ 26 at both Screening and Baseline visits. * Subjects with negative or mitigated answers on safety screening questionnaire for transcranial magnetic stimulation. * Negative pregnancy test in childbearing age women. * Subject is capable and willing to provide informed consent. * Subject is able to adhere to the treatment schedule.
Exclusion criteria
* Subject diagnosed according to the SCID I as suffering from any other major Axis I disorder, such as Psychotic Disorder, Bipolar affective disorder, OCD (MDD is not contraindicated when HDRS-21≤26). * Subjects diagnosed according to the SCID II as suffering from Severe Personality Disorder. * Subjects with significant suicidal risk as assessed by the investigator using the Beck Suicide Ideation scale, psychiatric interview or a history of attempted suicide in the past year. * Subject has a history of epilepsy or seizure (EXCEPT those therapeutically induced by ECT). * Subject has a history of significant head trauma with loss of consciousness for longer than 5 minutes. * Subject has a history of cranial surgery. * Subject has metallic particles in the eye or head (exclusive of mouth), implanted cardiac pacemaker or any intra-cardiac lines, implanted neurostimulators, intra-cranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical pumps. * Subject has severe and frequent headaches. * Subject has a history of significant hearing loss. * Subjects with a significant neurological disorder or insult including, but not limited to: * Any condition likely to be associated with increased intracranial pressure * Space occupying brain lesion * History of cerebrovascular accident * Transient ischemic attack within two years * Cerebral aneurysm * MMSE ≤ 24 * Parkinson's disease * Huntington's chorea * Multiple sclerosis * Subject with a history of substance abuse including alcoholism within the past 6 months (except nicotine and caffeine). * Inadequate communication with the patient. * Subject is under custodial care. * Subject is currently participating in another clinical study or enrolled in another clinical study within 30 days prior to this study. * Subject with unstable physical disease such as unstable cardiac disease. * Subject is currently on Benzodiazepine at a dose higher than 3 mg of Lorazepam or equivalent. * Subject has had previous treatment with TMS. * Women who are breast-feeding. * Women of childbearing potential and not using a medically accepted form of contraception when sexually active.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CAPS-5 Score | 5 weeks from baseline | CAPS-5 Score measured by change from baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate | 5 weeks from baseline | Response rate at the 5 week follow-up visit. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | 5 and 9 weeks | Measured by vital signs, physical & neurological examinations, lack of significant increase in suicide ideation, & other adverse event reporting. |
| Changes in Cognitive Scales | 5 and 9 weeks | Changes in MMSE and BSRT Scales |
Countries
Canada, Israel, United States
Outcome results
None listed